The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.

ABSTRACT: The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 20% relative reduction in prostate cancer mortality after 16yr [rate ratio (RR) 0.80], but centers varied by attendance, screen interval, biopsy compliance, contamination in the control arm, and treatments. We used a microsimulation model, calibrated to the ERSPC individual-level data, to predict influence of study features on the results. The relative reduction in prostate cancer mortality would have been somewhat larger with improved study features: increased attendance (90% attendance in all volunteer-based and 70% in all population-based centers, resulting in RR 0.77), a 2-yr screen interval (RR 0.75), and an 80% biopsy compliance (RR 0.79). The RR would have been substantially lower with a 30% attendanc

SUBMITTER: Heijnsdijk EAM 

PROVIDER: S-EPMC6800079 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature